SalioGen Therapeutics

United States
Prairie City, Iowa, United States, 01803

Company profile

SalioGen Therapeutics company profile

SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.

Business identity

Phone number
(650) 906-9468
Operating status
Closed
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2020-01-01, Year

Headquarters

Postal code
01803
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$135M
Last funding
Series B / $115M / 2022-01-05
Last equity funding
Series B / $115M
Investors
9
Lead investors
3
Founders
1
Articles
37

Founders and investors

Founders

Joseph Higgins

Lead investors

EPIQ Capital GroupGordonMD Global InvestmentsPBM Capital Group

Investors

Cystic Fibrosis FoundationD1 Capital PartnersEPIQ Capital GroupFidelityT. Rowe Price